All times are listed in CEST (Central European Summer Time)
Found 1 Presentation For Request "1324P"
1324P - Pembrolizumab as a monotherapy (P) or in combination with platinum-based chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumour proportion score (TPS) ≥50%: A real-world data (Israeli Lung Cancer Group)
- Elizabeth Dudnik (Petah Tikva, Israel)
Abstract
Background
Both P and PCT represent standard 1st-line treatment options for aNSCLC with PD-L1 TPS ≥50%. The two strategies have never been compared in a randomized trial.
Methods
256 consecutive patients (pts) with
Results
Baseline characteristics were well balanced, except for age and ECOG PS differences in favor of group B (Table). With median follow-up of 9.9 mo [IQR 2.7-18.9] and 6.7 mo [IQR 4.6-10.8] in groups A and B, respectively (p-0.003), 78% and 53% of pts stopped the treatment, and 57% and 30% of pts died in groups A and B, respectively. No statistically significant differences in TTF or OS between the groups were observed (Table). In the univariate analysis, ECOG PS (p-0.0002), age (p-0.01) and smoking history (p-0.003) significantly correlated with TTF; ECOG PS (p<0.0001) and age (p-0.0006) significantly correlated with OS; treatment group, sex, histology, presence of liver or brain metastases did not demonstrate a significant correlation with TTF or OS (p>0.1). In the propensity score matching analysis (n-106; 53 patients in each group matched for age, sex and ECOG PS), no differences in OS or TTF between the groups were observed (Table).
Group A (P; n-203) Group B (PCT; n-53) p-value Age, y (range) 68 (36-97) 63 (35-87) 0.02 Men, % 68 58 0.2 Smokers, % 91 89 0.8 Adenoca/sq cellcarcinoma/other, % 78/16/6 72/19/9 0.5 ECOG PS 0+1/2-4/NA, % 68/31/1 85/15/0 0.02 Weight loss >5%, % 26 32 0.7 Liver metastases, % 13 11 1.0 Brain metastases, % 27 26 1.0 OS, median (95%CI), mo 12.5 (9.8-16.4) 20.4 (10.8-NR) 0.08 TTF, median (95%CI), mo 4.9 (3.1-7.6) 7.9 (4.7-15.6) 0.09 Propensity score matching analysis (n-106) OS, median (95%CI), mo 13.3 (6.8-20.3) 20.4 (10.8-NR) 0.2 TTF, median (95%CI), mo 7.9 (2.8-12.7) 7.9 (4.7-15.6) 0.4
Conclusions
P and PCT in the real-world setting are associated with similar outcomes; with the limitations of the retrospective study design and short follow-up, P emerges as a preferable 1st-line treatment option for aNSCLC with PD-L1 TPS ≥50%. Results of subgroup analysis will be presented during the conference.
Legal entity responsible for the study
Israeli Lung Cancer Group.
Funding
Israeli Lung Cancer Group.
Disclosure
E. Dudnik: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): Boehringer Ingelheim, Roche, AstraZeneca, Pfizer, MSD, BMS, Novartis, Takeda. M. Moskovitz: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Boehringer Ingelheim, Roche, AstraZeneca, MSD, BMS, and Takeda. M. Wollner: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Boehringer Ingelheim, Roche, AstraZeneca, Pfizer, MSD, BMS, Takeda. A. Zer: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche, MSD, BMS, AstraZeneca; Research grant/Funding (self): BMS. J. Bar: Research grant/Funding (self): MSD, Roche, Boehringer Ingelheim, AstraZeneca and Pfizer; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD, Roche, Boehringer Ingelheim, AstraZeneca, Pfizer, BMS, Novartis, Takeda, Bayer, Vascular Biogenics, and AbbVie. All other authors have declared no conflicts of interest.